In	IN	O
terms	NNS	B
of	IN	I
the	DT	B
global	JJ	O
market	NN	O
,	,	B
India	NNP	O
currently	RB	O
holds	VBZ	O
a	DT	B
modest	JJ	O
1	CD	O
-	SYM	B
2	CD	O
%	NN	O
share	NN	O
,	,	B
but	CC	O
it	PRP	B
has	VBZ	I
been	VBN	B
growing	VBG	O
at	IN	O
approximately	RB	O
10	CD	O
%	NN	O
per	IN	O
year[27	NN	O
]	-RRB-	O
.	.	O

India	NNP	O
gained	VBD	O
its	PRP$	B
foothold	NN	O
on	IN	O
the	DT	B
global	JJ	O
scene	NN	O
with	IN	O
its	PRP$	B
innovatively	RB	O
-	HYPH	B
engineered	VBN	O
generic	JJ	O
drugs	NNS	O
and	CC	B
active	JJ	O
pharmaceutical	JJ	O
ingredients	NNS	O
(	-LRB-	O
API	NNP	O
)	-RRB-	O
,	,	B
and	CC	I
it	PRP	B
is	VBZ	I
now	RB	O
seeking	VBG	O
to	TO	B
become	VB	O
a	DT	B
major	JJ	I
player	NN	O
in	IN	O
outsourced	JJ	O
clinical	JJ	O
research	NN	O
as	RB	O
well	RB	B
as	IN	O
contract	NN	O
manufacturing	NN	O
and	CC	B
research	NN	O
.	.	O

There	EX	B
are	VBP	I
74	CD	O
U.S.	NNP	O
FDA	NNP	O
-	HYPH	B
approved	VBN	O
manufacturing	NN	O
facilities	NNS	O
in	IN	O
India	NNP	O
,	,	B
more	JJR	I
than	IN	O
in	IN	O
any	DT	O
other	JJ	B
country	NN	O
outside	IN	O
the	DT	B
U.S	NNP	O
,	,	B
and	CC	I
in	IN	O
2005	CD	O
,	,	B
almost	RB	I
20	CD	O
%	NN	O
of	IN	B
all	DT	I
Abbreviated	NNP	O
New	NNP	O
Drug	NNP	O
Applications	NNP	O
(	-LRB-	O
ANDA	NNP	O
)	-RRB-	O
to	IN	B
the	DT	I
FDA	NNP	O
are	VBP	B
expected	VBN	I
to	TO	B
be	VB	I
filed	VBN	O
by	IN	O
Indian	JJ	O
companies[21,27	NN	O
]	-RRB-	O
.	.	O

Growth	NN	O
in	IN	O
other	JJ	B
fields	NNS	O
notwithstanding	JJ	O
,	,	B
generics	NNS	O
are	VBP	B
still	RB	O
a	DT	B
large	JJ	O
part	NN	O
of	IN	B
the	DT	I
picture	NN	O
.	.	O

